Search Results for: 19

Theriva Biologics anuncia el nombramiento del Dr. Ramón Alemany en el cargo de vicepresidente sénior de descubrimiento de fármacos

May 23, 2023 15:40 ET -Con este nombramiento se espera contribuir al avance del programa de descubrimiento de Theriva y al fortalecimiento de la colaboración con el Institut Català d’Oncologia (ICO) y el Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)- ROCKVILLE, Maryland, May 23, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la […]

Theriva Biologics anuncia el nombramiento del Dr. Ramón Alemany en el cargo de vicepresidente sénior de descubrimiento de fármacos Read More »

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2023

May 11, 2023 22:48 ET – Prosigue la inscripción de pacientes en VIRAGE, el ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Presentación de datos del ensayo clínico de fase 1b/2a en curso de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2023 Read More »

Theriva™ Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 11, 2023 08:00 ET – Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at the 33rd European Congress of

Theriva™ Biologics Reports First Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

May 04, 2023 08:00 ET ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m.

Theriva™ Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) – April 13, 2023 08:00 ET ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer

Theriva™ Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Theriva Biologics anuncia la presentación de los datos de la cohorte 1 del ensayo clínico de fase Ib/IIa de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

– Los datos provisionales de farmacocinética y seguridad con enmascaramiento se presentarán en el 33.er Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas (ECCMID) – April 13, 2023 16:25 ET ROCKVILLE, Maryland, April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa diversificada de fase clínica que investiga

Theriva Biologics anuncia la presentación de los datos de la cohorte 1 del ensayo clínico de fase Ib/IIa de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas Read More »

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022

March 31, 2023 00:33 ET – Dosis al primer paciente de VIRAGE, un ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Dosis al primer paciente del ensayo de fase 1 patrocinado por investigadores de VCN-01 en pacientes con tumores cerebrales – – Presentación

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022 Read More »

Theriva™ Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

March 30, 2023 08:00 ET – Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety

Theriva™ Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results Read More »

Theriva™ Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

February 16, 2023 12:05 ET – Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb. 16,

Theriva™ Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »